BFLY vs GEHC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BFLY and GEHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BFLY and GEHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Butterfly Network designs and sells handheld ultrasound systems built on its proprietary Ultrasound-on-Chip technology, which replaces the traditional piezoelectric crystals in an ultrasound machine with a semiconductor sensor. That lets a single probe (the flagship iQ3) image the whole body and connect to a phone or tablet, and the company layers on subscription software, cloud storage, and AI tools that push clinicians toward higher-margin recurring revenue. Customers include hospitals, clinics, medical schools, and increasingly international and lower-resource settings where a $2,000-to-$5,000-range device is far cheaper than a cart-based system.

Full BFLY guide

GE HealthCare is the medical technology business spun off from the former General Electric conglomerate as an independent company. It is one of the world's largest makers of medical imaging and diagnostic equipment. Its product portfolio spans MRI, CT, X-ray, ultrasound, and molecular imaging systems, plus contrast agents and radiopharmaceuticals used in scans, patient monitoring devices, and a growing suite of healthcare software and AI tools that help clinicians interpret images and manage care. GE HealthCare makes money by selling these large imaging systems to hospitals and clinics, and importantly through recurring revenue from service contracts, maintenance, software, and consumables like contrast media. With a large installed base of equipment worldwide, the company benefits from steady demand for diagnostics, an aging global population, and the growing role of AI in radiology. Headquartered in Chicago, it serves healthcare providers across developed and emerging markets and competes among the top global medical imaging vendors.

Full GEHC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BFLY drivers: Software and recurring-revenue mix shift; iQ3 probe and hardware refresh cycle.
• GEHC drivers: Large installed base and recurring revenue; AI and software in imaging.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Butterfly remains unprofitable, with trailing losses of roughly $76M against about $103M of revenue as of Q1 2026, so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. For GEHC, gE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BFLY if you believe its drivers more; GEHC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BFLY and GEHC guides.

BFLY. As of mid-2026, Butterfly generated roughly $103M in trailing revenue while posting net losses, and it guided to full-year 2026 revenue of about $117M to $121M with an adjusted-EBITDA loss of roughly $21M to $25M. With a market cap in the $1.5B-to-$2.3B range after a large share-price run, the stock trades at a high multiple of sales, so the valuation embeds substantial future growth. The roughly $138M cash balance gives it a multi-year runway at current burn rates.

GEHC. GE HealthCare is valued as a defensive medical technology company with a large installed base and recurring service and consumables revenue. Investors weigh steady diagnostics demand and AI-driven product upgrades against competition and hospital capital-spending cycles. The valuation reflects a stable healthcare franchise with moderate growth and the optionality of expanding software and higher-margin businesses.

Headline figures (approximate, JUNE 2026): BFLY shows revenue (ttm) ~$103M, q1 2026 revenue growth ~25% YoY, fy2026 revenue guidance ~$117M to $121M, gross margin (q1 2026) ~69%; GEHC shows revenue (ttm) ~$19 to 21 billion, operating margin ~mid teens percent, net income (ttm) ~$2 billion or more, recurring revenue mix ~meaningful service and consumables.

BFLY and GEHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BFLY and GEHC exposure against your real portfolio. It is not an investment adviser.